What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “125 mg single-dose given by endoscopic-ultrasound (EUS) guided peripancreatic injection.”In the company’s words, NCT06080789 on ClinicalTrials.gov
- Tested for
- Acute Pancreatitis
- Main trialPhase 2
- “The goal of this clinical trial is to test the safety and effectiveness of a single dose of RABI-767 given by endoscopic ultrasound (EUS) guided peripancreatic injection in participants with predicted severe acute pancreatitis. The main question the study aims to answer is: • Is a single-dose of RABI-767 given by EUS-guided peripancreatic injection safe in patients with predicted severe acute pancreatitis. The study also aims to answer: • Is a single-dose of RABI-767 given by EUS-guided peripancreatic injection effective in treating patients with predicted severe acute pancreatitis.…”In the company’s words, NCT06080789 on ClinicalTrials.gov
Other drugs for Acute Pancreatitis
Coming up1
- DecPhase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Dec 2026 | A Study to Evaluate the Safety and Efficacy of a Single Dose of RABI-767 in Participants With Acute Pancreatitis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026